tbuckley/cabot-search huggingface dataset:
Studies with Applanation Water Tests
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Community Hospitals: an Under-Recognized Resource for Palliative Care
Authors: Sheila Payne, Chris Kerr, Sheila Hawker, David Seamark, Carol Davis, Helen Roberts, Nicola Jarrett, Paul Roderick, Helen Smith
Journal: Journal of the Royal Society of Medicine (2004)

In the UK there are concerns that, in certain groups of dying patients such as the old, those with non-cancer diagnoses and those in rural areas, the quality of care is unacceptably variable. There has been no systematic survey of the extent to which community hospitals provide general palliative care for such patients. Therefore, by means of a structured questionnaire we asked senior nurses/managers at all 478 community hospitals in the UK for information on staff expertise, facilities and specialist equipment, liaison arrangements with specialist palliative care providers, priorities, practice and policy in end-of-life care. Of the 346 hospitals (72%) that responded, only 28 were in urban areas. 73% of hospitals employed at least one nurse with additional training in palliative care, 72% had access to 24-hour specialist palliative care advice and 51% had separate overnight accommodation for relatives, but only 22% had designated palliative care beds. Most hospitals did not have written policies or guidelines for patient assessment or symptom control. These findings add to evidence that community hospitals represent an important resource to improve access to palliative care for groups that are currently under-served.
THE YELLOW FEVER.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Academia Meets the Market
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract P1-03-04: Response to cyclooxygenase-2 inhibition is regulated by collagen dense stroma
Authors: K Esbona, DR Inman, S Saha, LG Wilke, PJ Keely
Journal: Cancer Research (2016)

Abstract Women with dense breast have over four-fold risk for breast cancer and high breast density is correlated to increased collagen. In our previously characterized mouse model of MMTV-PyVT x Col1a1tm1jae, increased collagen levels in mammary tumors lead to enhanced tumor formation and progression. Additionally, high collagen density in vitro elevated expression of PTGS2, the gene for cyclooxygenase-2 (COX-2), by over four-fold. Because COX-2 over-expression is observed in 40% of invasive breast carcinoma cases and correlates with poor prognosis, we hypothesized that inhibition of COX-2 may be an effective target in the context of mammary tumors arising in dense tissue. Col1a1tm1jae (HD) or wild-type (wt) tumor mice were randomly assigned at 11 weeks of age to daily treatment with vehicle or celecoxib for 21 days. Tumors in HD mice were larger (p &amp;lt; 0.05) and expressed higher levels of COX-2 (p &amp;lt; 0.05) and PGE2 (p &amp;lt; 0.01). COX-2 and PGE2 expression levels were both decreased with COX-2 inhibition (wt and HD = p &amp;lt; 0.0001, for both markers). Cell proliferation decreased in both wt and HD tumors when COX-2 was inhibited (Epithelium wt and HD p &amp;lt; 0.0001; stroma wt = p &amp;lt; 0.05 and HD = p &amp;lt; 0.01). Notably, several cytokines, immune and stromal cell counts were elevated in HD tumors alone, and COX-2 inhibition reversed this effect. These findings indicate that COX-2 has a direct role in modulating tumor progression in dense matrices and it may be an effective therapeutic target for women with dense breast tissue. Citation Format: Esbona K, Inman DR, Saha S, Wilke LG, Keely PJ. Response to cyclooxygenase-2 inhibition is regulated by collagen dense stroma. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-03-04.
"THE EXPENSIVE 'POOR MAN'S MEDICINE'"
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Commentaire de travail de V. Cennamo et al., pp. 381
Journal: Endoscopy (2010)

See also: Can early precut implementation reduce endoscopic retrograde cholangiopancreatography-related complication risk? Meta-analysis of randomized controlled trialsEndoscopy 2010; 42(05): 381-388DOI: 10.1055/s-0029-1243992
ONE EFFECT OF THE FOOD AND DRUGS ACT.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clearance of bacteriuria on discontinuing oral contraception.
Authors: Colin Robertson, James Paton, Denis Evans, Lillian Miao, Charles Hennekens, Edward Kass
Journal: BMJ (1980)

the administration of intravenous sodium bicar- bonate, his urinary output rose to 50 ml/hour.However, by the next day blood urea had risen to 38 mmol/I (229 mg/100 ml) and the urate level was unchanged.Urgent haemodialysis was performed, with biochemical improvement; in particular, postdialysis urate was 0 50 mmol,l (8 40 mg/ 100 ml).Following a single haemodialysis his diuresis continued over the next three days and his recovery was otherwise uneventful, with no residual renal impairment.We agree that acute renal failure due to a nephrotoxic effect of alcohol is unlikely.In our case muscle damage was both apparent clinically and confirmed biochemically.How- ever, the uric acid level was also grossly ele- vated.The mechanism of acute renal failure as a consequence of myoglobinuria is uncertain although it has been suggested that other factors, including shock and acidosis, are important.'It is well recognised that hyperuricaemia occurs following muscle damage.'Additionally, hyperuricaemia may lead to acute renal failure in the absence of muscle damage.3Muscle damage may result from pressure necrosis following immobility during alcoholic stupor.4We suggest that the resulting hyperuricaemia is a major aetiological factor in the development of acute renal failure in this situation.In similar cases, priority should be given to the estimation of uric acid level and if it is grossly elevated then urgent alkalinisation to increase uric acid solubility and dialysis to reduce uric acid load is indicated.In such circumstances haemodialysis is to be greatly preferred to peritoneal dialysis, as urate clearance is significantly greater.3
Sulforaphane Enhances the Therapeutic Potential of TRAIL in Prostate Cancer Orthotopic Model through Regulation of Apoptosis, Metastasis, and Angiogenesis
Authors: Sharmila Shankar, Suthakar Ganapathy, Rakesh K. Srivastava
Journal: Clinical Cancer Research (2008)

The purpose of this study was to examine the molecular mechanisms by which sulforaphane enhances the therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in prostate cancer.Cell viability and apoptosis assays were done by XTT and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay, respectively. Tumor-bearing mice were treated with vehicle, sulforaphane, TRAIL, and sulforaphane plus TRAIL. Markers of apoptosis, angiogenesis, and metastasis were measured by immunohistochemistry.Sulforaphane enhanced the therapeutic potential of TRAIL in PC-3 cells and sensitized TRAIL-resistant LNCaP cells. Sulforaphane-induced apoptosis in PC-3 cells correlated with the generation of intracellular reactive oxygen species (ROS), collapse of mitochondrial membrane potential, activation of caspase-3 and caspase-9, and up-regulation of DR4 and DR5. Sulforaphane induced the expression of Bax, Bak, Bim, and Noxa and inhibited the expression of Bcl-2, Bcl-X(L), and Mcl-1. The quenching of ROS generation with antioxidant N-acetyl-L-cysteine conferred significant protection against sulforaphane-induced ROS generation, mitochondrial membrane potential disruption, caspase-3 activation, and apoptosis. Sulforaphane inhibited growth of orthotopically implanted PC-3 tumors by inducing apoptosis and inhibiting proliferation and also enhanced the antitumor activity of TRAIL. Sulforaphane up-regulated the expressions of TRAIL-R1/DR4, TRAIL-R2/DR5, Bax and Bak and inhibited the activation of nuclear factor-kappaB P13K/AKT and MEK/ERK pathways in tumor tissues. The combination of sulforaphane and TRAIL was more effective in inhibiting markers of angiogenesis and metastasis and activating FOXO3a transcription factor than single agent alone.The ability of sulforaphane to inhibit tumor growth, metastasis, and angiogenesis and to enhance the therapeutic potential of TRAIL suggests that sulforaphane alone or in combination with TRAIL can be used for the management of prostate cancer.
CORRESPONDENCE
Authors: W. N. Goldsmith
Journal: British Journal of Dermatology (1935)

Journal Article CORRESPONDENCE Get access W. N. Goldsmith W. N. Goldsmith Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology and Syphilis, Volume 47, Issue 7, 1 July 1935, Page 317, https://doi.org/10.1111/j.1365-2133.1935.tb09876.x Published: 01 July 1935
Data Error, Missing Sentence, and Misnumbered References
Authors: Ben Moscovitch, Josh Rising
Journal: JAMA (2017)

Medicare & Medicaid Services (CMS) would need to adopt the change through regulations.Because claim forms are updated infrequently, missing this opportunity could result in a delay of an additional decade or more.Incorporating device identifiers of implants has support from across the health care industry-including health plans, hospital systems, clinical societies, and the Medicare Payment Advisory Commission. 4 Last year, the FDA and CMS also expressed support, as did the Office of Inspector General of the Department of Health and Human Services, which oversees the Medicare program.Senators Chuck Grassley (R-IA) and Elizabeth Warren (D-MA) have also worked with X12 to press for the addition of device information.
Table of Contents
Authors: Cerrene Giordano, Weng Yew, Graciela Spivak, Henry Lim, Yik Yew, Robert Kantor, Prarthana Dalal, David Cella, Jonathan Silverberg, Alexander Fogel, Joyce Teng, Kavita Sarin, Tor Shwayder, Ragna Thorleifsdottir, Sigrun Sigurdardottir, Bardur Sigurgeirsson, Jon Olafsson, Hannes Petersen, Martin Sigurdsson, Johann Gudjonsson, Andrew Johnston, Helgi Valdimarsson, Jashin Wu, Bruce Strober, Peter Hansen, Ole Ahlehoff, Alexander Egeberg, Abrar Qureshi, Debbie Robertson, Hernan Valdez, Huaming Tan, Robert Wolk, Mary Hill, Azin Pishkenari, Taylor Braunberger, April Armstrong, Cory Dunnick, Gustavo Deza, Ana Brasileiro, Marta Bertolı ´n-Colilla, Laia Curto-Barredo, Ramon Pujol, Ana Gime´nez-Arnau, Khalaf Kridin, Shira Zelber-Sagi, Mogher Khamaisi, Arnon Cohen, Reuven Bergman, Naiara Barbosa, Stanislav Tolkachjov, Rokea El-Azhary, Mark Davis, Michael Camilleri, Marian Mcevoy, Alina Bridges, David Wetter, Landon Stigall, David Brodland, John Zitelli, Justin Leitenberger, Howard Rogers, John Chapman, Ian Maher, Matthew Fox, Chris Harmon, Evans Bailey, Peter Odland, Ashley Wysong, Tim Johnson, Oliver Wisco, Manuel Valdebran, Amira Elbendary, Krishna Arudra, Kara Torres, Inas Elattar, Dirk Drph
Journal: Journal of the American Academy of Dermatology (2016)
Cough Syncope
Authors: S. Caller
Journal: BMJ (1953)

<h3>Background</h3> Tumour Infiltrating Lymphocytes (TILs) is a modality of ACT under development in solid tumours. Unfortunately, prior lymphodepletion is a key step that frequently requires the administration of antibiotics and antifungics for long periods of time. Although there is evidence that gut microbiome may influence tumour response in patients treated with checkpoint-inhibitors, it has not been extensively studied in ACT.<sup>1</sup> <h3>Methods</h3> Analysis of gut microbiome at three different times (T1: before lymphodepletion, T2: before TIL infusion and T3: day +15) has been performed in patients treated with ACT between 2018 and 2020. The composition and structure of the sampled microbial communities was assessed through the amplification and sequencing the V3-V4 variable regions of the 16S rRNA gene. The Illumina Miseq sequencing 300×2 approach was used. Taxonomic assignment of phylotypes was performed using a Bayesian Classifier trained with Silva database version 132 (99% OTUs full-length sequences). The following metrics were measured: observed OTUs (community richness), evenness (Pielou’s index) and Shannon’s diversity index. Differential abundance of taxa was tested using ANCOM test and Kruskal Wallis test. <h3>Results</h3> A total of 21 patients have been treated with TILs between 2018 and 2020 at our institution. 67% were female. Median age was 43 (range 26–70 years). All patients had stage IV pre-treated solid tumours: 55% cervical cancer, 33% melanoma, 10% lung adenocarcinoma and 5% head and neck cancer. Median previous treatment lines was 3 (range 2–4). Analysis of gut microbiome has been performed in 3 of these patients: one achieved PR, one progressed and the third one suffered an unexpected death. 971 phylotypes were detected. Analysis revealed differences in terms of observed OTUs, evenness and Shannon’s index when comparing T1 and T2 with T3. At T3 a tendency towards less diversity and evenness was observed when compared with T1 and T2 (H 3.0, p-value 0.083, not statistically significant). Comparing the distribution of considered taxa in ACT responders vs. non-responders, we observed significant differences for both class (Bacteroidia, Clostridia and Gammaproteobacteria) and order (Bacteroidales, Lactobacillales, Clostridiales and Enterobacteriales) levels. <h3>Conclusions</h3> A deep change in gut microbiome composition along TILs therapy was observed. Though preliminary, differences between responders and non-responders were observed but should be confirmed in larger populations. <h3>Reference</h3> Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. <i>Science</i> 2018;<b>359</b>:97–103.
Thrombotic thrombocytopenic purpura—hemolytic uremic syndrome (TTP‐HUS) following treatment with deoxycoformycin in a patient with cutaneous T‐cell lymphoma (Sezary syndrome): A case report
Authors: Joseph W. Leach, Trinh Pham, Dimitris Diamandidis, James N. George
Journal: American Journal of Hematology (1999)
Anemia
Journal: JAMA (1980)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Combination of an acetyl CoA carboxylase inhibitor with therapeutics that promote fatty acid oxidation moderately improves efficacy in a preclinical NASH model
Authors: Archana Vijayakumar, Isabel Olson, Sangeetha Mahadevan, Ting Wang, Shiva Zaboli, Maria Toteva, James Trevaskis, David Breckenridge, Jamie Bates
Journal: Journal of Hepatology (2020)
MARTINUS WILLEM BEIJERINCK (1851-1931)
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal